Metraipolis › archive › dc_a926f002bd76

Substitution of ifosfamide for cyclophosphamide in the TI-CE regimen: pharmacology and dose justification in a patient with refractory metastatic germ-cell… — Europe PMC PMID:41125910

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41125910
DOI
10.1007/s00280-[numero omesso]-0
License (as archived)
solo-consultazione
Archived
2026-11-09T03:57:52.170Z
SHA-256 of the archived text
3b6a70493226e1f00a7662898b46dcc4fde686036889007aa70d912b16861a98
Stable URL of this page
https://metraipolis.com/documento/dc_a926f002bd76

How to cite

Substitution of ifosfamide for cyclophosphamide in the TI-CE regimen: pharmacology and dose justification in a patient with refractory metastatic germ-cell… — Europe PMC PMID:41125910 — Europe PMC (en), https://europepmc.org/article/MED/41125910 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_a926f002bd76 (Metraipolis archive dc_a926f002bd76, sha256 3b6a70493226e1f00a7662898b46dcc4fde686036889007aa70d912b16861a98)
BibTeX
@misc{dca926f002bd76,
  title = {Substitution of ifosfamide for cyclophosphamide in the TI-CE regimen: pharmacology and dose justification in a patient with refractory metastatic germ-cell… — Europe PMC PMID:41125910},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41125910},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_a926f002bd76; sha256 3b6a70493226e1f00a7662898b46dcc4fde686036889007aa70d912b16861a98},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41125910. Agents can read the archived copy with the MCP tool read_document.